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SYMPOSIUM
Iron and Malaria Interactions: Research Needs
From Basic Science to Global Policy1,2
Andrew M. Prentice and Sharon E. Cox
MRC International Nutrition Group, London School of Hygiene and Tropical Medicine, London, UK, and MRC Keneba, The Gambia
ABSTRACT
The resurgence in interest and concern regarding the potentially malign interactions between iron administration and malaria infections,
especially in young children and pregnant women, has generated a research agenda that is both broad and deep. This paper highlights some of
the key questions under 5 headings: basic science; clinical science and epidemiology; technological developments; country level planning; and
global policy. At a time of unparalleled progress in basic science, which is illuminating the mechanisms by which iron interacts with infectious
organisms, it is concluded that there are good medium-term prospects for achieving policy breakthroughs based on a secure foundation of
disease-nutrient interactions. However, it is also stressed that there is much that can be done in the interim, especially in relation to health
systems and implementation research that can empower systems to integrate iron interventions with programs for malaria prevention,
surveillance, and treatment. Adv. Nutr. 3: 583–591, 2012.
Introduction
The premature termination of the iron arms of the now in-
famous Pemba trial (1), due to an excess of serious adverse
events among children receiving iron and folic acid, forced
the WHO to issue new policy guidance in which the recom-
mendation for universal iron supplementation was replaced
by one advocating targeted supplementation (2). There has
since been a vigorous debate about how to safely administer
iron to infants, children, and pregnant women living in ma-
laria-endemic areas (3). This has led to a policy vacuum at
both the global and country levels because the proposed
targeted approach is very difﬁcult to implement and implies
treatment of iron deﬁciency (ID) as opposed to prevention,
thus putting millions of children at risk of the silent seque-
lae of ID. This was the background to the current sympo-
sium “Tackling Iron Deficiency and Anemia in Infants and
Young Children in Malaria-Endemic Areas: Moving From
Controversy Toward Guidance for Safe, Effective, and Feasi-
ble Policies and Programs” summarized in the accompany-
ing papers (4–7). The purpose of this paper is to identify the
residual research needs and make recommendations as to
their prioritization given the urgency with which we need
to surmount the policy stasis imposed by the Pemba results.
Although further research on iron–malaria interactions is
urgently required and will undoubtedly inform the policy
agenda, some elements of it will inevitably take several or
many years to mature, and this should not be allowed to in-
hibit interventions against ID designed against the back-
ground of our current, albeit inadequate, knowledge. The
final paper of this symposium addresses that challenge (8).
The research needs, listed in Table 1, are summarized
under 5 headings: basic science; clinical science and epide-
miology; technological developments; country level plan-
ning; and global policy. The table represents an executive
summary so readers are encouraged to view the table before
continuing. The needs identified represent the views of the
authors and should not necessarily be interpreted as the col-
lective view of the symposium participants.
Basic science
If we assume a high probability of some malign interac-
tions between exogenous iron administration and pathoge-
nicity of infections, it is essential that the basic science
investigating the potential mechanisms is used to inform
1 Published as a supplement to Advances in Nutrition. Presented as part of the symposium
entitled “Tackling Iron Deficiency and Anemia in Infants and Young Children in
Malaria-Endemic Areas: Moving from Controversy towards Guidance for Safe, Effective and
Feasible Policies and Programs” given at the Experimental Biology 2011 meeting, April 10,
2011, in Washington, DC. The symposium was sponsored by the American Society for
Nutrition and supported in part by the U.S. Army Military Infectious Disease Research
Program. The symposium was chaired by Lynnette M. Neufeld and Angus Scrimgeour. The
Guest Editors for this symposium were Lynnette M. Neufeld and Rafael Flores-Ayala. Guest
Editor disclosures: Neither Guest Editor had conflicts to disclose. The opinions expressed in
this publication are those of the authors and are not attributable to the sponsors or the
publisher, Editor, or Editorial Board of Advances in Nutrition.
2 Author disclosures: A. M. Prentice and S. E. Cox, no conflicts of interest.
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Table 1. A summary of research needs ranging from basic science to global policy1
Research need Practical implications Likely time to interventions
Basic science
Mechanisms of iron–malaria interactions
Hepatic and/or blood stage effects?
Acute (e.g., NTBI) and/or chronic (e.g., iron loading)
effects?
Systemic and/or enteric effects?
Will inform optimization of iron interventions:
chemical composition, dose, timing, fortification
vs. supplementation, etc.
Short to medium
Mechanisms of iron interactions with other pathogens
Malaria-associated bacteremias
Iron-dependent bacteria (especially TB)
Iron-dependent viral infections (e.g., HIV, hepatitis C)
Will ﬁll extensive knowledge gaps relevant to design
of iron-related therapeutic (e.g., iron withholding)
and preventive interventions
Medium to long
Hepcidin–iron axis as a mediator of immune responses
Hepcidin as component of innate immunity
Hepcidin–iron axis as potential modulator of adaptive
immune responses, especially vis-à-vis vaccines
Possibility of using hepcidin agonists or antagonists
as therapeutic agents and/or vaccine adjuvants
Medium to long
Biology of iron acquisition in an infectious environment
Is ID and/or anemia partly an adaptive response to
infectious threats?
Are there windows of opportunity for safe iron
acquisition between intercurrent infections?
Should deﬁnitions of ID and anemia cutoffs be
modified in infectious environments?
Must infections be reduced before tackling ID?
Short to medium
Clinical science and epidemiology
Risks vs. benefits
Health metrics research on pros and cons of iron
interventions
Further research on iron, brain development, and
cognition
Necessary to balance iron aversion and policy stasis
created by Pemba results. Reminder that most
interventions (especially vaccines) have risks.
Balanced judgment required
Short
Establishing safe modes of iron administration
Very large-scale trials to test safety of iron in malarial
regions (theoretical need but not feasible in practice
to assess serious adverse outcomes and mortality)
Can only be assessed against nominal proxy outcomes
such as malarial infection, NTBI, altered microbiota
The ethics Catch-22 (see text) will prevent any new
trials in high-risk environments without malaria
surveillance and control. Small trials can never
cancel out Pemba
Probably never
Screening
Is the Pemba substudy conclusion that iron is safe in
children with ID secure? Requires replication.
Is the risk vs. benefit equation dependent on markers of
ID?
Would screening ever be a practical option?
Screening implies treatment; is this desirable?
Good clinical practice recommends assessment and
diagnosis of a condition before intervention. Pemba
data show this to be critical and WHO adopted a
screening resolution, but is it practicable?
Short to medium
Supplements vs. fortifiers vs. foods
Wide research agenda exists regarding the efficacy and
safety of supplements vs. fortifiers
Iron as part of multinutrient packages for home-based
fortification (powders or lipid-based pastes) are
currently the favored options but still require validation
Food-based solutions are recognized as difficult to
achieve at present (but see below)
Research in these domains will likely yield the most
immediate benefits and help fill the
policy/practice void
Immediate and onward
Life-course approaches
Can a life-course approach (e.g., enhancing iron status
of mothers-to-be, cord clamping) reduce the need to
intervene in infancy?
May direct interventions away from pregnancy and
young childhood when iron–malaria interactions
are most damaging
Short
Technological developments
Formulation of supplements and fortifiers
Further optimization of chemical composition, dose
level, mode of administration, etc.,.
Controlled slow release in duodenum and less residual
unabsorbed iron for intestinal microbiota is the challenge
Much research already completed, but new basic
science findings can inform further optimization
Efficacy and tolerability (low side-effect profile) tends
to correlate with cost; breaking this relationship
is critical for low-income settings
Immediate and onward
Crop technology
Accelerated transgenic crop enhancement programs
Can staple foods with enriched iron content (e.g.,
BioCassava Plus) help bridge the growing gap
between flesh food supply and demand ?
Medium and long term
Point-of care diagnostics
Design, optimization, testing, and production of very
low cost point-of-care tests for iron deficiency
Inexpensive, simple, and reliable point-of-care tests
will be required if a screening approach is to be
endorsed. Even if not endorsed diagnosis of ID is
clearly important in tropical medicine
Immediate and onward
(Continued)
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the design of clinical and epidemiological studies. These
should have appropriate endpoints and sufﬁcient power to
investigate differential effects between subpopulations or
environmental interactions. This is particularly important
considering the ethical impossibility of conducting another
Pemba-type study.
Mechanisms of iron–malaria interactions
Blood or liver stage effects? Does iron promote plasmodial
infection via effects on the liver stage or blood stage or both?
Because erythrocytes are packed with iron and present the
parasite with the challenge of detoxifying the iron as hema-
zoin, many observers ﬁnd it hard to envisage that ID could
limit blood stage development and hence that supplementa-
tion would augment blood stage virulence, although it can-
not be ruled out. In contrast, soon after this symposium,
Portugal et al. (9) reported compelling evidence, at least in
mice, that hepcidin-mediated iron redistribution from he-
patocytes to macrophages in mice carrying a blood stage
parasitemia prevented secondary infection by sporozoites
(so-called superinfection) by starving the exoerythrocytic
forms of iron (see references 5 and 10 for abbreviated sum-
maries of these extensive experiments and for discussions of
their implications). This work ﬁrmly establishes the iron–
hepcidin axis as an arm of innate immunity and paves the
way for numerous follow-up studies; for instance, to estab-
lish how this protection is altered by giving exogenous iron.
It also confirms a key role for the iron-regulatory hormone
hepcidin, which may emerge as a superior biomarker for
iron status (see the following) and which will undoubtedly
be the target of extensive clinical and molecular research
as we further interrogate its biology.
Acute and/or chronic effects of iron? In the post-Pemba
search for possible explanatory mechanisms, much attention
has focused on the possibility that the unphysiologically
large bolus dose of iron, especially when given between
meals as recommended to avoid food-based iron chelators,
could overwhelm the capacity of transferrin to remove it
safely from the basolateral membranes of enterocytes. This
might lead to a transient peak of nontransferrin-bound
iron (NTBI), a possibility discussed in some detail by Dewey
and Baldiviez (7) in the accompanying paper. NTBI could
lead to oxidant damage and/or ready availability of iron to
plasmodial parasites and/or provision of substrate for
iron-seeking bacteria. The last of these might be a special
concern given that bacteremias are common comorbid
conditions in malaria (11,12) and may have led to the seri-
ous adverse outcomes in Pemba (1). Given the high level of
malaria transmission in Pemba at this time, chronic asymp-
tomatic malaria would have been prevalent and the occur-
rence of fever triggering attendance at a health facility may
have been the result of superimposed bacterial or viral in-
fections rather than a direct result of the malaria infection.
Several ongoing studies are attempting to address the issues
surrounding NTBI, the measurement of which poses signif-
icant technical challenges with skepticism surrounding the
validity of some methods.
An alternative interpretation of the mechanism of iron
toxicity is that it results from a gradual iron accumulation
and is more likely to occur in iron-replete children. Both
of these possibilities are supported by analysis of the Pemba
data: ﬁrst, time-to-event plots for adverse outcomes in the
iron- and noniron-receiving arms only started to diverge af-
ter w 200 d of supplementation and, second, in the sub-
study, supplementary iron was beneficial to iron-deficient
children and only harmful to those who were iron replete
at baseline (13).
Distinguishing between acute and chronic toxicity of
iron, if indeed there is a clear distinction, would be enor-
mously helpful in designing optimal iron protocols.
Table 1. (Continued )
Research need Practical implications Likely time to interventions
Country level planning
Endemicity of malaria and ID
Map regions where malaria and ID overlap
Understand modifying factors such as altitude, season
Governments can make better plans for iron
interventions and avoid inaction in nonmalarial
areas
Immediate and onward
Integration of programs
How best to integrate intermittent preventive therapy,
bed nets, and iron?
Potential adverse reactions can be avoided if
interventions against malaria either precede
or accompany iron interventions
Immediate and onward
Global policy
Assessing risks vs. benefits
See above
Necessary to balance iron aversion and policy stasis
created by Pemba results. Reminder that most
interventions (especially vaccines) have risks.
Balanced judgment required
Short
Universal vs. targeted approaches
See above
Resolution and guidance required on whether to
adopt screening and a targeted approach to
combating ID in malarial areas
Short
Global trends in malaria
Monitor global trends in malaria
Monitor trends in prevention, surveillance, and
treatment
Important to keep iron–malaria issue in an appropriate
perspective against rapidly changing patterns of
disease
Immediate and onward
1 ID, iron deficiency; NTBI, nontransferrin-bound iron.
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Systemic and/or enteric effects? The questions posed above
all relate to potential systemic effects of orally administered
iron. It is also possible that iron could have profound effects
on the microbiota of the gut as most enteric bacteria require
iron. Interestingly, the biﬁdobacteria have a low iron need
and breast milk is low in iron and keeps it tightly bound
to lactoferrin, for which there are speciﬁc receptors that
allow efﬁcient uptake of what little iron is present. Recently,
Zimmermann et al. (14) showed that relatively low levels of
iron given in fortiﬁed biscuits to children in Cote d’Ivoire al-
ter the microbiota in an unfavorable direction and result in
elevated levels of fecal calprotectin, a marker of gut inflam-
mation. This raises several further research questions: Could
the enteric inflammation occasionally disrupt the barrier
function of the gut to such an extent that it allows bacterial
translocation leading to septicemia? Will lower doses of oral
iron minimize these effects on the microbiota? If so, what
are the lowest doses that will retain efficacy against ID?
Can iron formulations be designed that optimize duodenal
iron uptake to such an extent that there is insufficient
residual iron entering the lower gut to disrupt the normal
flora?
Mechanisms of iron interactions with other pathogens
Although not directly related to the issue of iron–malaria in-
teractions, the issues that have been placed in such sharp fo-
cus by the Pemba trial are already stimulating a renewed
interest and numerous research programs into the possible
effects of iron on susceptibility to other pathogens. Impor-
tant new findings are likely to emerge within the next 5 y.
In this respect, it should be remembered that the conclusion
that the adverse events noted in Pemba were due to interac-
tions between iron and malaria is based almost solely on an
indirect inference drawn from the fact that there is no ma-
laria in the region of Nepal where a parallel trial found no
overall adverse effects. It should also be noted that the Nepal
trial did not have a substudy to determine whether there
might have been opposite effects by initial iron status, as
suggested in the Pemba trial. Thus, iron interactions with
other infections may be highly pertinent.
Iron-dependent bacterial infections. A broad range of bac-
teria are highly iron-dependent and possess iron-response
elements that modify their gene expression to cope with a
varying iron supply. Many have captured specialist iron-
ac quisition apparatus from other bacteria to be able to
colonize low iron niches (such as the systemic circulation
of humans). Often these genes are concentrated in the ge-
nomic regions associated with high pathogenicity and hence
show evidence of the centrality of iron to host-pathogen
competition for a nutritional resource (15). To the best of
our current knowledge, these attributes are not shared by
any other nutrient, and hence it makes sense to concentrate
our research efforts in this direction until we better under-
stand the biology of these interactions.
To take a single prominent example, Mycobacterium tu-
berculosis, the causative organism for tuberculosis, is highly
iron dependent. It has long been suspected that iron
administration can exacerbate tuberculosis and accelerate
mortality (16,17), and the molecular and genomic mecha-
nisms underpinning the host-pathogen battle for iron are
now starting to become clearer (18). Emerging data not yet
in the public domain are starting to point to a (potentially
critical) role for hepcidin in mediating some of these effects
(H. Drakesmith, personal communication).
There is a series of clear, although very challenging, research
questions in relation to iron and bacterial infections (in addition
to those previously listed vis-à-vis the potential effects of NTBI
and gut damage), among which are the following:Which bacteria
are especially sensitive to host iron supply and, given that some
can strip iron even when tightly bound to host transporters,
how does iron status and oral iron administration affect bacterial
survival, growth, and virulence? How does the malaria-induced
diversion of iron from the systemic circulation and hepatocytes
into macrophages (via hepcidin up-regulation) affect host suscep-
tibility to bacterial infection (and in particular to intracellular or-
ganisms such as Mycobacteria and Salmonella that colonize the
macrophage)? What implications do these biological mechanisms
have for strategies to combat ID in environments where infections
are still prevalent? Canmanipulation of host iron status, by means
of iron chelators and/or hepcidin agonists or antagonists, be used
therapeutically to inhibit bacterial growth and allow host adaptive
immunity to complete the task of elimination?
Iron-sensitive viral infections. In an analogous manner to
bacteria, there is strong evidence that many viral infections
are iron dependent (19) and that the course of infections, in-
cluding HIV, may be accelerated by high iron status and ex-
ogenous iron administration (16). Emerging evidence again
implicates a role for hepcidin in mediating a novel iron-
dependent arm of the innate immune system (20). These
early hints challenge us with a similar set of research ques-
tions for viruses as set out for bacteria.
The hepcidin–iron axis as a mediator of immune
responses
Reference has already been made to some of the emerging
evidence that the hepcidin–iron axis constitutes a newly dis-
covered arm of the innate immune system (9,20,21). In
some senses, this merely confirms all of the preexisting evi-
dence, some of it known for more than half a century, that
iron redistribution resulting in the systemic hypoferremia of
the acute phase response is a beneficial anti-infective process
(15). But, what is so exciting about the rapidly emerging
hepcidin story is that it opens windows into the functioning
of a series of black boxes that have hitherto concealed their
biological secrets. Once we understand the molecular cogs,
gears, and linkages, the sensors and effectors, that control
iron homeostasis in the face of an infectious threat, then
they will be amenable to therapeutic interventions based
either on pharmacological interventions or, in the context
of Third World health, on a better understanding of when
to administer (or withhold) iron, how, how much, and to
whom. It is a reasonable prediction that hepcidin research
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will have clarified many of our current iron and infection
imponderables within a decade from now.
Biology of iron acquisition in an infectious
environment
The elements, discussed previously, of the interactions
between host iron status and infections coalesce into an
interesting question that is considered heretical by public
health interventionists, namely, is ID, and the consequent
anemia, adaptive in the sense that it has optimized survival
in highly infectious environments? This highly plausible the-
sis that receives repeated, although by no means unanimous,
observational support (22–24) is worthy of further research
because, if true, it lays out a clear pathway for interventions;
we must reduce the threat of infections before we can opti-
mize cognitive function and physical performance by raising
iron status to levels above those that have existed at least for
the past 10,000 y in most population groups. The imperative
of coordinating iron interventions with malaria protection
policies has been repeatedly emphasized in this symposium
(4,8). This call should be extended to all infections.
A second question about the biology of iron in un-
hygienic environments is this: Are there windows of op-
portunity for safe iron acquisition between intercurrent
infections, and, if so, can we design intervention strategies
to work in harmony with this natural biology? Emerging
evidence strongly supports the view that hepcidin responds
to an infectious threat within minutes or hours to lock out
exogenous iron (via down-regulation of the iron efﬂux pro-
tein ferroportin on enterocytes) (25) and lock down body
iron (via an analogous effect in the macrophage) (25). Evi-
dence from recently treated malaria patients also indicates
that hepcidin decreases rapidly when the infectious threat
has passed (much more rapidly than C-reactive protein
and ferritin, for instance) and hence reopens pathways for
iron absorption and redistribution to the erythron, allowing
rapid recovery of iron equilibrium and hemoglobin levels
(26). What are the public health implications of this biology?
There may be long windows and short windows. Long
windows would typically be associated with seasons. Our
research in rural Gambia reveals a strong seasonality of
most infections including malaria (highest in and shortly
after the rains), and hence an appropriate strategy might
be to concentrate on building up iron stores during the
low-infection dry season (but note that if high iron status
per se makes individuals more susceptible to infection,
this may not be a desirable course to take). Short windows
may last only days or weeks. To capitalize on opportunities
to boost iron status during these windows, we would need
a point-of-care diagnostic that rapidly registered readiness
to receive supplemental iron. Hepcidin appears to have the
necessary attributes to become such a marker.
Clinical science and epidemiology
Estimating risks versus beneﬁts of iron interventions
Almost all health interventions carry some risks. This is cer-
tainly true of most drugs and vaccines. Preclinical animal
studies and phase I trials explore mechanisms, establish op-
timal dose levels likely to maximize beneﬁt while minimiz-
ing risk, and test for grossly overt adverse reactions. Phase
II and III trials scale the studies up to better estimate levels
of risk and beneﬁt, which are then reported to licensing
authorities, and, if approved, the interventions are introduced
into medical practice. Postmarketing surveillance is then used
to audit rare adverse outcomes that might not have been seen
even in large phase III trials, and many compounds are with-
drawn at this stage. The problem with iron interventions is
that they have been used for decades without any such trials.
When they have been tested, the outcome was almost always
hemoglobin level and/or anemia rates. Other outcomes such
as cognition, immune function, and human capital endow-
ment were rarely assessed. Therefore, when the worrying out-
come of Pemba emerged, it focused minds almost entirely on
the negative attributes of iron. During the Lyons Consultancy
held byWHO (2), a plea was made for health metrics research
that would allow a balanced appraisal of the pros and cons of
iron interventions. That call has not been adequately met and
represents an important outstanding research need.
Such analysis requires more secure input data on the con-
sequences of ID and on the potential advantages of reversing
it. Further research on iron, brain development, and cogni-
tion is especially needed.
Establishing safe modes of iron administration
The current mindset in the ﬁeld is that intravenous iron is
deﬁnitely contraindicated in malarial areas and that iron
tablets and syrups represent a highly unphysiological means
of administering iron that may lead to pathology (as dis-
cussed previously). As discussed by Dewey and Baldiviez
(7) in this symposium, food fortiﬁcation, either centrally
or at point of consumption via Sprinkles or lipid-based
nutrient supplements, is currently favored, but is it safe?
Dewey and Baldiviez list the emerging data and conclude
that
Results from 6 home fortification studies in malaria-en-
demic areas (some not yet published) showed no increased
risk of adverse effects. Most of these studies, however, had
small to moderate sample sizes, so severe adverse events
could not be adequately assessed. There is also a lack of in-
formation on the potential modifying effect of initial iron
status on treatment effects. Although the evidence to date
suggests that home fortification with iron in malaria-
endemic areas is safe, additional researchwould be valuable.
However, it is very challenging, if not impossible, to
obtain conclusive evidence on the safety of home fortifica-
tion in malaria-endemic areas. Severe adverse events asso-
ciated with iron consumption are likely only seen where
infectious disease control is lacking, yet it would be uneth-
ical in this type of setting to conduct studies without pro-
viding any services to monitor and treat infectious disease,
including malaria. A huge sample size would be required
to rule out a modest increase in severe adverse effects (7).
This neatly articulates the Catch-22 faced by investiga-
tors. There seems no ethical way around this, and, therefore,
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although replication or refutation of the Pemba results
would be extremely valuable, it will never be forthcoming
and future actions must be designed against this constraint.
An alternative approach is to assess iron interventions
against a panel of known or suspected adverse outcomes
that may lie on a pathway to serious adverse events and
death. The present panel of proxy outcomes includes
malaria infection and parasitemia rates (including placental
infection), NTBI levels, alterations in gut microbiota,
markers of gut inﬂammation, growth retardation, and, in
sufﬁciently large trials, other clinical outcomes such as bac-
teremias and hospitalizations. It is hoped that the basic sci-
ence research into mechanisms summarized previously may
point to other intermediate proxies of possible harm.
Is screening for ID a realistic option?
The statement arising from the WHO Lyon Consultancy ad-
vocated that in malaria-endemic areas, iron should only be
administered to children shown to be iron deﬁcient on
screening (2). This symposium revealed ambivalence on
this matter. Crowley et al. (6) were asked to summarize
the current prospects for ﬁeld-friendly methods for such
screening, yet other papers implicitly concluded that screen-
ing is not really a practical option because a) it would be too
costly and complicated to administer within the sorts of
health systems where the need is greatest and b) by deﬁni-
tion, screening implies treatment as opposed to prevention
and may leave millions of children vulnerable to the debili-
tating effects of ID.
Another problem is that, although the Pemba substudy
very clearly demonstrated that the harmful effects of iron
were limited to children who were iron replete (as judged
by having zinc protoporphyrin levels <80 mmol/mol hemo-
globin) (1,13), another study from Tanzania has yielded
an apparently opposite effect in a trial using a multiple mi-
cronutrient intervention that contained iron (27). The latter
trial assessed ID/sufficiency according to serum ferritin
levels, which could contribute to the apparent conflict.
Clearly, this is an issue that needs to be resolved. Basic
science findings might help here. The former result (i.e.,
that iron-replete children show adverse effects) is consonant
with the chronic iron-loading mechanism. The latter result
is consonant with the acute NTBI-type mechanism because
intestinal iron absorption is up-regulated in iron-deficient
children and may facilitate a greater uptake of nonphysio-
logical unchelated iron.
Assuming that screening for ID is an effective tool (and,
irrespective of Pemba results, good clinical practice favors
treatments based on a clear diagnosis), then the practicalities
of this need to be evaluated in real-life settings together with
a cost–benefit analysis. The stakes are high because the costs
are measured in children’s lives rather than the costs of treat-
ment because iron is very inexpensive.
Supplements vs. fortiﬁers vs. foods
There is a large and important research agenda to de-
ﬁne the optimal mode of administering iron to poor
populations. Some key issues are listed in the Table 1 but
are not discussed further in this paper as they have been ex-
tensively covered in the accompanying paper by Dewey and
Baldiviez (7).
Life-course approaches
Can a life-course approach (e.g., enhancing iron status of
mothers-to-be, cord clamping) reduce the need to intervene
in pregnancy and infancy? Certainly there is evidence that
each of these interventions can have an impact on iron status
(28,29), but trials have not yet been published that report
results from a truly integrated life-course approach. One
element that would need to be considered is that even pre-
conception iron administration might increase the chances
of a mother having malaria in pregnancy if the overall
iron status is a determinant of risk, as is currently thought
to be the case (5,24).
Technological developments
Formulation of supplements and fortiﬁers
Avery wide range of compounds are already used as iron sup-
plements or fortiﬁers, yet development of new compounds
still progresses in the search for the optimal compromise be-
tween efﬁcacy, side-effect proﬁle, and cost. The issue of cost is
particularly important in the developing country context un-
der consideration here, and, unfortunately, there tends to be a
reciprocal relationship between cost and optimal efﬁcacy and
side-effect proﬁle. The side effects of iron compounds (such
as constipation, black stools, gastrointestinal discomfort, diz-
ziness) are much more signiﬁcant than they might at ﬁrst ap-
pear because, together with the absence of any obvious
therapeutic beneﬁt to the patient, they are responsible for
very low levels of long-term compliance with standard iron-
folate formulations offered to pregnant women.
Note that safety is not included among the triangulation
points listed for optimization of iron compounds. This is
because (with the exception of intravenous iron administra-
tion, which has been known for some decades to exacerbate
malaria) before Pemba, most compounds were assumed to
be safe. The Pemba trial has changed this, and the observa-
tions of Zimmermann et al. (14) that even modest levels of
fortifying iron can induce gut inﬂammation (14) complicate
the picture still further. In the past, one strategy to combat
low absorption was simply to give more iron, but this is
no longer an acceptable response. As discussed previously,
the strategy now being used by many is to minimize the
amount of iron given. This drives a need for higher absorp-
tion rates to maintain efﬁcacy, and this represents an impor-
tant research need. Good examples of the necessary studies
were published recently (30–32) and already indicate that,
for instance, 3 mg of iron as iron EDTA may have similar
efficacy to 12.5 mg of iron as iron sulfate and might thus
reduce residual iron for the microbiota.
Crop technology
It is recognized that the costs and relative scarcity of ﬂesh
foods and other sources of highly bioavailable iron put
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them beyond the reach of many poor people much of the
time (33). Accelerated transgenic crop enhancement pro-
grams offer one route to try to overcome this roadblock
and are receiving appropriate funding from the Bill and Me-
linda Gates Foundation and other funding bodies as well as
from the private sector. The research needs range from the
initial genetic engineering to produce high iron varieties,
through ﬁeld trials of yields, to consumer trials of accept-
ability, efﬁcacy trials, investigations of social marketing
strategies to enhance take-up, and, ﬁnally, large-scale effec-
tiveness monitoring. With such a large agenda, it will be
some years before a major impact can be made, and in the
meantime, chemical fortiﬁcation represents a much simpler
route.
Point-of-care diagnostics
An ability to make a rapid and secure diagnosis of ID at the
primary health care level would represent a major step for-
ward, irrespective of whether future policy encompasses the
screening option. Graded dipstick and paper-based tests are
available for many analytes and for diagnosis of several con-
ditions. A decade ago, malaria dipsticks were newly on the
market, yet WHO recently evaluated no fewer than 41
brands, indicating the pace at which technological develop-
ments can occur. In the accompanying paper, Crowley et al.
(6) discuss the current state-of-play regarding ﬁeld assess-
ment of tools for ID. Their paper focuses mostly on ﬁeld-
friendly transdermal methods for assessing hemoglobin
because no other methods are yet available for testing. At-
tempts to develop a ﬁeld-friendly transdermal ﬂuores-
cence–based method for assessing zinc protoprophyrin
are in progress, and such an instrument would be a signif-
icant step forward if it proves robust, reliable, and very low
cost.
Other initiatives, driven in particular by the Bill and
Melinda Gates Foundation’s Biomarkers of Nutrition for
Development program through National Institute of Child
Health and Human Development/NIH, are in progress to
improve community-level screening for iron status (34).
These are concentrating significant investment on the issue
of how to adjust survey data on ferritin to compensate for
high levels of inflammation, a procedure applicable to sur-
vey data but not viable for individual patient assessment in
which low ferritin will always have high specificity but
very low sensitivity.
Our group has early data indicating that hepcidin has the
potential to form the basis of an excellent point-of-care di-
agnostic to indicate safe and ready to receive iron, especially
now that effective antibody-based assays have been devel-
oped (the absence of which delayed progress in the ﬁeld
for several years). There is a compelling logic to the use of
hepcidin because it is the key iron-regulatory hormone
that integrates signals from transferrin saturation, hypoxia,
hepatic iron, inﬂammation, and infection and is both a sen-
sor of iron status and an effector of iron absorption and dis-
tribution (21). We believe that this sets out an important
research need with excellent prospects for success in the
development of new tools both for individual clinical diag-
nosis of ID and for population screening. Appropriate
cutoffs must be evaluated and then transferred to affordable
tests such as those being developed for paper-based
diagnostics.
Country-level planning
This symposium was organized by the Micronutrient Initia-
tive in response to the frustrations voiced by many country-
level planners and policymakers regarding what they see as a
void in the guidance from international bodies (4). In fact,
there is plenty of enabling research that countries can be
doing to circumvent the perceived policy stasis.
Mapping endemicity of malaria and ID
Map regions where malaria and ID overlap. Most coun-
tries have varied topography that affects disease transmis-
sion (especially infections such malaria and helminths that
affect ID) and diet. Likewise, regional differences in poverty
and the health and transportation infrastructure will affect
access to health services. Regional differences in malaria
transmission are not always predictable (35) and hence
require country-speciﬁc data. Health departments can
perform basic surveys to map out the areas in which ID
and malaria overlap to the greatest extent. A partial example
is provided in Table 2, which lists anemia rates (assessed by
Hemocue) identified in a nationwide survey of The Gambia
conducted by the National Nutrition Agency (36). The sur-
vey was integrated with a parallel survey of vitamin A defi-
ciency but, in this case, did not simultaneously assess
malaria rates in the same samples. The survey clearly iden-
tifies where interventions are most required and in this set-
ting because malaria is highly seasonal, offers at least a
partial solution to the iron–malaria conundrum if the opti-
mal solution of minimizing malarial transmission cannot
yet be attained, namely, to attack the problem in the dry sea-
son and in the most needy areas.
Understand modifying factors such as altitude and
season. As implied in the example given above, health de-
partments could reﬁne their intervention policies if they
have a clear understanding of the factors such as altitude,
Table 2. Example of within-country regional differences in
anemia rates1,2
Division
(geographic area)
Prevalence of anemia in
children (1–5 y)
Moderate (%) Severe (%)
Banjul (urban) 31 6
Kanifing (urban) 74 3
Western (rural coastal) 66 9
Central River (rural) 77 17
Lower River (rural) 22 20
North Bank (rural) 32 12
Upper River (rural) 87 35
1 Moderate deficiency = hemoglobin ,110 g/L; severe deficiency = hemoglobin
,70 g/L.
2 Reproduced from Reference 36 with permission.
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water sources, vegetation, season, and regional food supplies
that affect the prevalence of both ID and malaria. This rep-
resents a primary research need for any countries for which
such knowledge is not yet secure.
Integration of programs
How best to integrate intermittent preventive therapy,
bed nets, insecticides, and iron. Almost all of the research
needs outlined above would be made redundant if malaria
could be eradicated. This is not yet attainable, but it is pos-
sible for countries to develop integrated approaches that
combine antimalarial interventions such as intermittent
preventive therapy, insecticide-treated bed nets, indoor
residual spraying, and availability of malaria treatment reg-
imens at the village level with administration of iron in-
terventions. Many countries, often with the support of
international bodies, are testing such programs with a
view to scaling them up. This seems the most viable and de-
sirable of all routes forward at the current time [see also the
observations of Stoltzfus (8) in the accompanying paper].
Global policy research needs
Many of the research needs already outlined, for example,
the health metrics research into costs versus beneﬁts of
iron programs and the issue of universal versus targeted ap-
proaches, are relevant to global policy. A ﬁnal signiﬁcant is-
sue relates to how the iron–malaria problem may evolve in
the future.
Global trends in malaria
Monitor trends in prevention, surveillance, treatment,
and global trends in malaria. The good news on the hori-
zon is that malaria rates have recently decreased very mark-
edly in several countries in sub-Saharan Africa (37,38). The
precise causes of these decreases and whether they will be
sustained in the future remain to be evaluated, but the
trends provide some real grounds for optimism, and further
and wider monitoring of these trends will help inform fu-
ture policy options. Such monitoring and the subsequent
collation of such data at the country, regional, and global
levels by WHO therefore represent another important re-
search goal.
Conclusions
The Pemba trial has become a nemesis in the minds of many
health interventionists and has certainly created a most un-
desirable policy paralysis that, among many other counteref-
forts, has stimulated the present symposium. From a
research standpoint, however, it has proved to be a very
powerful wake-up call and has stimulated an unprecedented
resurgence in efforts to better understand the highly com-
plex interactions between iron and malaria (and other mi-
croorganisms). This resurgence has coincided with a
decade in which our knowledge of the molecular pathways
regulating iron metabolism has exploded and in which a
key central regulator of iron metabolism, hepcidin, was dis-
covered. The basic sciences are therefore in a very strong
position to grapple with the issues. Pemba has also been
beneﬁcial in attracting research funding to the ﬁeld, and
there are many ongoing studies focusing on iron–malaria in-
teractions, most notably through the Iron and Malaria pro-
gram managed by National Institute of Child Health and
Human Development/NIH with substantial funding from
the Bill and Melinda Gates Foundation. Pemba has also
been helpful from a research standpoint in reestablishing
an ethical equipoise that once again makes it possible to con-
duct randomized, controlled trials using placebo arms with-
out iron; in fact, it is now regrettably more difficult to
include iron than to exclude it in some settings.
Research will ultimately clear the murky windows
through which we are trying to see our way to formulating
policy, but until such a time, the current imperative at the
country level is to progress with action. The most logical
course is to prioritize programs for malaria reduction and
treatment and then to join these with iron programs, the op-
tions for which have been set out in some of the accompa-
nying papers (5,8).
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